Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | GCLC | P48506 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11381471 | 0.85 | CHRM1 (0.38) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11489484 | 0.82 | CA2 (0.41) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| Chloromethane SCHEMBL28143162 | 0.82 | CA2 (0.64) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3914888 | 0.80 | CA2 (0.56) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8923812 | 0.79 | CA2 (0.61) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| Trichloroacetic Acid SCHEMBL6132326 | 0.78 | CA2 (0.54) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL9104718 | 0.76 | CA2 (0.52) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8943729 | 0.76 | FOLH1 (0.46) | — | |
| SCHEMBL500233 | 0.76 | CA2 (0.46) | CA2MAPK1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6114 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1215298-A | — | — | None | — | — | JP | disclosed |
| EP-1805316-B1 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF CIS-3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES EMPLOYING HYDROLASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1805316-A2 | METHOD FOR PRODUCING THE ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | Sanofi-Aventis Deutschland GmbH (DE) | 2007-07-11 | — | — | EP | disclosed |
| EP-1599433-B1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2006015716-A2 | METHOD FOR PRODUCING THE ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-16 | — | — | WO | disclosed |
| EP-1599433-A1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076390-A1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040137582-A1 | Methods for manufacturing polysaccharide derivatives | RENSSELAER POLYTECHNIC INSTITUTE | 2004-07-15 | — | — | US | disclosed |
| WO-2004024774-A2 | METHODS FOR MANUFACTURING POLYSACCHARIDE DERIVATIVES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-0594621-A1 | PROCESS FOR ENZYMATICALLY PREPARING ENANTIOMER-FREE ESTERS AND ALCOHOLS | Roche Diagnostics GmbH (DE) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993002034-A1 | PROCESS FOR ENZYMATICALLY PREPARING ENANTIOMER-FREE ESTERS AND ALCOHOLS | BOEHRINGER MANNHEIM GMBH (DE) | 1993-02-04 | — | — | WO | disclosed |
| EP-0274277-B1 | A PROCESS FOR THE ENZYMATIC SEPARATION OF THE OPTICAL ISOMERS OF RACEMIC OXAZOLIDINONIC DERIVATIVES | Montedison S.p.A. (IT) | 1993-01-27 | — | — | EP | disclosed |
| WO-1990009446-A1 | CUTINASE | PLANT GENETIC SYSTEMS N.V. (BE) | 1990-08-23 | — | — | WO | disclosed |
| US-4933290-A | REACTING WITH AN ESTER, ACID, OR ANHYDRIDE IN THE PRESENCE OF A LIPASE IMMOBILIZED ON A POROUS CARRIER | MONTEDISON S.P.A. (IT) | 1990-06-12 | — | — | US | disclosed |
| JP-H01215298-A | METHOD FOR OPTICALLY RESOLVING (+-)-1-PARA SUBSTITUTED PHENYLETHANOL | ARAKAWA CHEM IND CO LTD | 1989-08-29 | — | — | JP | disclosed |
| EP-0274277-A2 | A process for the enzymatic separation of the optical isomers of racemic oxazolidinonic derivatives | Montedison S.p.A. (IT) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040137582-A1 | Methods for manufacturing polysaccharide derivatives | SI, MGAM, IDUA | CA2 2688/4885MAPK1 1765/4885SLC1A3 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.